Oculis’ Post

View organization page for Oculis, graphic

3,960 followers

Following our recent Phase 2 RELIEF data for licaminlimab (also known as OCS-02), our novel anti-TNFα antibody eye drop candidate, the Oculis team had the opportunity to attend the 2024 @European Dry Eye Society Congress (#EuDEC 2024). We enjoyed the opportunity to discuss the data, which delivered further evidence to support the potential of our #PrecisionMedicine approach for the treatment of dry eye disease (#DED), a growing area of unmet need that affects nearly 40 million people in the US alone.   The RELIEF trial was an exploratory study designed to achieve three specific objectives: to evaluate the efficacy of licaminlimab on the signs of DED, to confirm the TNFR1 genetic biomarker as a predictor of response and to select the primary sign efficacy endpoint for a future Phase 3 trial. The trial met all three of these objectives, with positive topline data complementing two prior successful Phase 2 studies, during which the TNFR1 genetic biomarker was identified as a predictor of high responders to therapy. Excitingly, improvement of multiple signs of DED were observed in the full trial population, with more pronounced effect in the subpopulation with a TNFR1-related genotype, consistent with earlier trial results and laying the groundwork for progression towards a Phase 3 study.   For more information on the RELIEF topline results including important information on forward-looking statements, see our press release here: ur press release here: https://bit.ly/4bWdQw0

  • No alternative text description for this image
Tirso Alonso, MD, MBA, MHA

Senior Global Medical Director, Global Medical Affairs, MindMed Biopharmaceutical

4mo

Looking forward to this treatment option.

Like
Reply
Arum Wu, PhD

Senior Scientist, Pharma Research and External Scientific Innovation, Bausch and Lomb

4mo

Exciting! I am curious if a topical administration of the anti-TNFa scFv can penetrate the posterior segment (vitreous humor and neuroretina, for example).

Like
Reply
See more comments

To view or add a comment, sign in

Explore topics